Compass Pathways (NASDAQ:CMPS) Downgraded by Wall Street Zen to Strong Sell

Compass Pathways logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Compass Pathways from “sell” to “strong sell,” although the broader analyst consensus remains “Moderate Buy” with an average price target of $23.36.
  • CMPS opened at $11.57, with a $1.60 billion market capitalization and a share price ranging from $4.88 to $15.87 over the past year.
  • Compass Pathways reported a quarterly loss of $1.88 per share, missing the $0.39 consensus estimate by $1.49; institutional investors own 46.19% of the company.
  • MarketBeat previews top five stocks to own in December.

Compass Pathways (NASDAQ:CMPS - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Company assumed coverage on shares of Compass Pathways in a research report on Monday, July 27th. They set an "equal weight" rating and a $13.00 target price for the company. Wolfe Research reissued an "outperform" rating on shares of Compass Pathways in a report on Tuesday, July 7th. Royal Bank Of Canada lowered their price objective on shares of Compass Pathways from $22.00 to $21.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. BTIG Research raised their price objective on shares of Compass Pathways from $14.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, July 7th. Finally, Compass Point set a $25.00 price objective on shares of Compass Pathways in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $23.36.

View Our Latest Stock Analysis on CMPS

Compass Pathways Stock Performance

NASDAQ:CMPS opened at $11.57 on Friday. The stock has a market cap of $1.60 billion, a P/E ratio of -2.50 and a beta of 2.55. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. The business's 50-day moving average price is $12.91 and its two-hundred day moving average price is $10.38. Compass Pathways has a twelve month low of $4.88 and a twelve month high of $15.87.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, equities analysts predict that Compass Pathways will post -1.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

Several institutional investors and hedge funds have recently made changes to their positions in CMPS. Eagle Health Investments LP increased its holdings in shares of Compass Pathways by 35.6% in the first quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company's stock worth $11,394,000 after buying an additional 541,039 shares during the period. Orbimed Advisors LLC purchased a new stake in Compass Pathways during the 1st quarter valued at about $6,363,000. Affinity Asset Advisors LLC boosted its holdings in Compass Pathways by 454.2% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company's stock valued at $6,130,000 after acquiring an additional 908,483 shares during the period. Eversept Partners LP purchased a new stake in Compass Pathways during the 1st quarter valued at about $3,749,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in Compass Pathways by 23.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 399,506 shares of the company's stock worth $4,970,000 after acquiring an additional 76,297 shares during the last quarter. Institutional investors own 46.19% of the company's stock.

About Compass Pathways

(Get Free Report)

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company's lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.

Read More

Analyst Recommendations for Compass Pathways (NASDAQ:CMPS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Compass Pathways Right Now?

Before you consider Compass Pathways, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.

While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines